ARS Pharmaceuticals Inc
SPRY
View Detailed Chart
8.070USD
-0.490-5.72%
Close 03/27, 16:00（ET）Quotes delayed by 15 min
266.85MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-5.72%
5 Days
-1.22%
1 Month
-13.04%
6 Months
-16.98%
Year to Date
-30.73%
1 Year
-35.39%
View Detailed Chart
TradingKey Stock Score of ARS Pharmaceuticals Inc
Currency: USD Updated: 2026-03-27Key Insights
ARS Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 26.67.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ARS Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
ARS Pharmaceuticals Inc Highlights
StrengthsRisks
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 280826.67% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 84.28M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 84.28M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is -4.64, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 88.21M shares, decreasing 10.51% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.50M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.06.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
26.667
Target Price
+211.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ARS Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ARS Pharmaceuticals Inc Info
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Ticker SymbolSPRY
CompanyARS Pharmaceuticals Inc
CEOLowenthal (Richard E)
Websitehttps://ars-pharma.com/
Related Instruments
-2.10%
-1.92%
+0.49%
+2.48%
+0.58%
-0.88%
-0.98%
-1.24%
-0.51%
-1.96%
-1.02%
+0.34%
-0.19%
-1.55%
-4.56%
0.00%
-0.55%
-2.51%
-2.86%
-0.83%Popular Symbols
248.800
-4.090 (-1.62%)
167.520
-3.720 (-2.17%)
67465.460
+881.410 (+1.32%)
275.340
+1.990 (+0.73%)
2052.660
+52.660 (+2.63%)
361.830
-10.280 (-2.76%)
4532.810
+40.290 (+0.90%)
100.862
+0.253 (+0.25%)
1.149
-0.001 (-0.10%)
159.598
-0.654 (-0.41%)
